Jemincare
Jemincare, officially known as Jemincare Group, is a prominent player in the pharmaceutical and healthcare industry, headquartered in China (CN). Founded in 2005, the company has established a strong presence in various operational regions, focusing on innovative solutions in drug development and manufacturing. Specialising in the research and production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms, Jemincare is recognised for its commitment to quality and compliance with international standards. The company has achieved significant milestones, including partnerships with global pharmaceutical firms, which have bolstered its market position. With a diverse portfolio that includes oncology, cardiovascular, and central nervous system products, Jemincare stands out for its dedication to advancing healthcare through cutting-edge technology and rigorous research. Its notable achievements reflect a robust commitment to improving patient outcomes and enhancing global health.
DitchCarbon Score
How does Jemincare's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jemincare's score of 5 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Jemincare's reported carbon emissions
In 2023, Jemincare reported total carbon emissions of approximately 8,076,560 kg CO2e. This figure includes about 6,540 kg CO2e from Scope 1 emissions and approximately 8,070,020 kg CO2e from Scope 2 emissions. Compared to previous years, there has been a slight decrease in total emissions, with 2022 emissions at about 7,868,110 kg CO2e and 2021 emissions at approximately 8,104,020 kg CO2e. Despite these figures, Jemincare has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of formal commitments or climate pledges indicates a potential area for improvement in their sustainability strategy. As the company continues to operate within the pharmaceutical industry, addressing carbon emissions will be crucial for aligning with global climate goals and enhancing their environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 12,890 | 00,000 | 0,000 |
| Scope 2 | 8,091,130 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jemincare is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
